Dec. 04, 2019: Innovative Cellular Therapeutics (ICT) announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for ICTCAR014 (next generation CD19-targeting CAR-T cell therapy) that expresses a dominant negative PD-1 protein to block immunosuppression by cancer cells.
Data presented in November at the Society for Immunotherapy of Cancer (SITC) represents objective response rate of over 92%, the ICTCAR014 program highlights our accelerated and de-risked approach for developing novel immunotherapies. https://fda.einnews.com/pr_news/503959110/innovative-cellular-therapeutics-announces-fda-clearance-of-ind-for-its-dominant-negative-pd-1-armored-next-generation-car-t-cell-therapy
